Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/monash-ivf-group-ltd" target="_blank" data-smartkarma-citation="entities:18130:1" rel="noopener">Monash IVF (MVF AU)</a> has received a revised proposal from the consortium comprising Genesis Capital Investment Management and WHSP Holdings to acquire 100% of the shares in the company.</li>
<li>The indicative cash price offered under the proposal is A$0.90/share, up from A$0.80/share earlier. The revised offer price represents the highest amount the consortium is prepared to offer.</li>
<li>The proposal is valid until April 21, 2026. The Monash IVF Board is assessing the proposal and has appointed financial and legal advisors.</li>
</ul>



Monash IVF (MVF AU) has received a revised proposal from the consortium comprising Genesis Capital Investment Management and WHSP Holdings to acquire 100% of the shares in the company.
The indicative cash price offered under the proposal is A$0.90/share, up from A$0.80/share earlier. The revised offer price represents the highest amount the consortium is prepared to offer.
The proposal is valid until April 21, 2026. The Monash IVF Board is assessing the proposal and has appointed financial and legal advisors.


Monash Ivf (MVF AU): Revised Takeover Offer Seems Fertile